Blood coagulants | Tenderlake

Blood coagulants

Contract Value:
GBP 500M -
Notice Type:
Contract Notice
Published Date:
07 January 2022
Closing Date:
14 February 2022
Location(s):
UK UNITED KINGDOM
UKD NORTH WEST (ENGLAND) (UK UNITED KINGDOM)
Description:
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B, for a period of 24 months with an option to extend.
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 18 - Fresh Frozen Plasma

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 7 - Factor VIII Inhibitor Bypassing Fraction

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 13 - Von willebrands factor - Plasma Derived

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 12 - Factor VIII/ von willebrands factor

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 6 - Porcine Factor VIII - susoctocog alfa

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 5 - Recombinant Factor VII

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 4 - rFIX - Standard Half Life

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 3 - nonacog beta pegol (rFIX EHL)

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 2 - albutrepenonacog alfa (rFIX EHL)

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 1 - eftrenonacog alfa (rFIX EHL)

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 16 - Prothrombin Complex dried

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 15 - Fibrinogen Concentrate

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 14 - Von willebrands factor - Recombinant

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 17 - Protein C Concentrate

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 10 - Factor XIII - Plasma Derived

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 11 - Factor XIII - Recombinant

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 9 - Factor X

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.


Lot 8 - Factor IX - High Purity Factor IX

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

Download full details as .pdf
The Buyer:
The NHS Commissioning Board (operating under the name of NHS England)
CPV Code(s):
33141530 - Blood coagulants